1. EU Member States and the European Medicines Agency (EMA). Report on pharmacovigilance tasks 2019–2022. 2023. https://www.ema.europa.eu/en/documents/report/report-pharmacovigilance-tasks-eu-member-states-european-medicines-agency-ema-2019-2022_en.pdf. Accessed 19 Mar 2023.
2. Durand J, Dogné J-M, Cohet C, Browne K, Gordillo-Marañón M, Piccolo L, et al. Safety monitoring of COVID-19 vaccines: perspective from the European Medicines Agency. Clin Pharmacol Ther. 2023;113:1223–34.
3. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP): product- or population-specific considerations. I. Vaccines for prophylaxis against infectious diseases. P I. 2013. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-product-or-population-specific-considerations-i-vaccines-prophylaxis-against-infectious-diseases_en.pdf. Accessed 19 Mar 2023.
4. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Guide on methodological standards in pharmacoepidemiology (Revision 10). EMA/95098/2010. http://www.encepp.eu/standards_and_guidance. Accessed 19 Mar 2023.
5. Mahaux O, Bauchau V, Van Holle L. Pharmacoepidemiological considerations in observed-to-expected analyses for vaccines. Pharmacoepidemiol Drug Saf. 2016;25:215–22.